Información del artículo
Resumen
La enfermedad de Parkinson no es frecuente que aparezca antes de la edad de 40 años (5% de los pacientes). Aportamos un caso de gestación en una paciente de 33 años,portadora de una enfermedad de Parkinson. La paciente era tratada con levodopa asociada con benzerazida. No observamos ningún efecto adverso sobre la gestación y el feto. Se detectó un agravamiento moderado de los síntomas de la enfermedad de Parkinson. Se ha realizado una revisión de la bibliografía.
Summary
Parkinson’s disease begins before the age of 40 in only 5% of patients. We report a case of pregnancy in a 33-year old woman with Parkinson’s disease. The patient was treated by levodopa associate with benze-razid. No effect was observed on the pregnancy and the fetus. Only the symptoms were moderately worsened. A literature review is performed.
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.J. aminoff.
Enfermedad de Parkinson y otros trastornos extrapiramidales.
Harri-son. Principios de Medicina Interna II, 14, pp. 2681-2689
[2.]
B. Tolosa Sarró.
Enfermedad de Parkinson y otros trastornos del movimiento.
Medicina Interna II, 13, pp. 1490-1498
[3.]
R.K. Olney, M.J. Aminoff.
Debilidad muscular, movimientos anormales e inestabilidad.
Harrison.Principios de Medicina Interna I, 14, pp. 122-136
[4.]
A. Brodal.
Neurological anatomy in relation to clinical medicine.
Oxford, 3,
[5.]
E.R. Kandel.
Principles of neural science.
3,
[6.]
T. Wichmann.
Parkinson disease and basal ganglia: lessons from the laboratory and from neurosurgery.
Neuroscientist, 1 (1995), pp. 236-243
[7.]
O.S. Gershanik.
Parkinson of early onset.
Parkinson’s disease and movement disorders, pp. 191-204
[8.]
GE Jr Morgan, M.S. Mikhail.
Anesthesia for patients with neurologic an psyquiatric diseases.
Clinical anesthesiology, pp. 505-616
[9.]
E.M. Yun, B.A. Meyer, V.M. Parisi, A.C. Santos.
Neurologic and muscular diseases.
Anesthetic and obstetric management of high-risk anesthesia, 10 (1996), pp. 134-169
[10.]
R.H. Edwards.
Neural degeneration and the transport of neu-rotransmitters.
Ann Neurol, 34 (1993), pp. 638-642
[12.]
N. Quinn.
Drug treatment of Parkinson’s disease.
B Med J, 310 (1995), pp. 575-581
[13.]
D.A. Bennett.
Prevalence of parkinsonian signs and associated mortality in a community population of older people.
N Engl J Med, 334 (1996), pp. 771-777
[14.]
Th Routiot, S. Lurel, E. Denis, P. Barbarino-Monnier.
Maladie de Parkinson et grossesse: case clinique et revue de la literature.
J Gynecol Obstet Biol Reprod, 29 (2000), pp. 454-457
[15.]
W.J. Weiner, A.E. Wang.
Movement disorders.
A comprehensive survey,
[16.]
I. Shoulson.
The Parkinson study group. Effect of deprenyl on the progression of dissability in early Parkinson’s disease.
N Engl J Med, 321 (1989), pp. 1364-1371
[17.]
A. Barbeau.
Etiology of Parkinson’s disease: a research strategy.
Con J Neurol Sci, 11 (1984), pp. 24-28
[18.]
T.D. Bird.
Enfermedad de Alzheimer y otras demencias pri-marias.
Harrison. Princi-pios de Medicina Interna, 14, pp. 2672-2680
[20.]
F. Jacquemard, J.C. Palaric, H. Allain, J.R. Giraud.
Maladie de Parkinson et grossesse.
J Gynecol Obstet Biol Reprod, 19 (1990), pp. 461-463
[21.]
H. Allain, D. Bentue-Ferrer, D. Milon, P. Moran, F. Jacquemard, G. Defawe.
Pregnancy and Parkinson: a case report without problem.
Clin Neuropharmacol, 12 (1989), pp. 217-219
[23.]
M.C. Ball, H.J. Sagar.
Levodopa in pregnancy.
Mov Disord, 10 (1995), pp. 115-119
[24.]
P. Hagell, P. Odin, E. Vinge.
Pregnancy in Parkinson’s disease: a review of literature and a case report.
Mov Disord, 13 (1998), pp. 34-38
[25.]
D.G. Cook, H.L. Klawans.
Levodopa during pregnancy.
Clin Neuropharmacol, 8 (1985), pp. 93-95
[26.]
A.E. Kanter, A.H. Klawans.
Postencephalitic parkinsonism complicated by pregnancy.
Am J Obstet Gynecol, 39 (1939), pp. 334-337
[27.]
J.O. Donalson.
Movement disorders.
pp. 74-91
[28.]
S.N. Bellur.
Alteraciones neurológicas en el embarazo.
Medicina clínica en obstetricia, pp. 1046-1964
[29.]
C. Tobiassen, K. Brazo, O.M. Kohler.
Pregnancy and Parkin-son’s disease.
Ugeskr-Laeger, 153 (1991), pp. 1210-1211
[30.]
J.J. Nora, A.H. Nora, G.L. Way.
Cardiovascular maldevelop-ment associated with maternal exposure to amantadine.
Lancet, 2 (1975), pp. 607
[31.]
B.B. Pandit, D. Chitayat, A.L. Jefferies, A. Landes, I.U. Qamar, G. Koren.
Tibial hemimelia and tetralogy of Fallot associated with first trimester exposure to amantadine.
Reprod To-xicol, 8 (1994), pp. 89-92
[32.]
J.K. Lamar, F.J. Calhoun, A.G. Darr.
Effects of amantadine hydrochloride on cleavage and embryonic development in the rat and rabbit.
Toxicol Appl Pharmacol, 17 (1970), pp. 272-277
[33.]
I. Turkali, P. Braun, P. Krupp.
Surveillance of bromocriptine in pregnancy.
JAMA, 247 (1982), pp. 1589-1591
[34.]
C. Weil.
The safecty of bromocriptine in hyperprolactinemic female infertility: a literature review.
Curr Med Res Opin, 10 (1986), pp. 172-195
[35.]
R.P. Glick, A. Hart.
Diagnóstico y manejo de los tumores encefálicos durante el embarazo.
pp. 1500-1518
[36.]
Roura A. Cabero, Hiperprolactinemia..
Prolactinoma. Protocolos de la Sociedad Española de Ginecología y Obstetricia.
[37.]
Tejerizo López LC, Sánchez Sánchez MM, García Robles RM, Tejerizo García A, Leiva A, Morán E et al
[38.]
J. Benito-León, F. Bermejo, J. Porta-Etessam.
Pregnancy in Parkinson’s disease: a review of literature and a case report.
Mov Disord, 14 (1999), pp. 194-203
[39.]
N. Kodama, K. Tsubota, Y. Ezumi.
Reproductive studies of lisuride hydrogen maleate.
Kiso to Rinsho, 15 (1981), pp. 2299
[40.]
H. Shimazu.
Study on oral administration of FPF 1100 prior to pregnancy and lactation period in rats.
Yakury to Chiryo, 23 (1995), pp. 57
[41.]
R.E. Staples, P.A. Mattis.
Teratology of L-dopa.
Teratology, 8 (1973), pp. 238-242
[42.]
Roche Laboratories.
Levodopa (Larodopa®) for the relief of symptoms associated with Parkinson’s disease and syndrome.
Clin Pharmacol Ther, 11 (1982), pp. 921-924
[43.]
J. Tarradellas, C. Gomar, S. Suárez.
Analgoanestesia en la gestante con enfermedad neurológica.
Principios fundamentales y bases de aplicación clínica, pp. 699-733
[44.]
J. Prilusky, R.P. Deis.
Effect of L-dopa on milk ejection and prolactin release on lactating rats.
J Endocrinol, 67 (1975), pp. 397-401
[45.]
H. Kaulhausen, T. Oney, G. Leyendecker.
Inhibition of the rennin-aldosterone axis and prolactin secretion during pregnancy by L-dopa.
Br J Obstet Gynaecol, 89 (1982), pp. 483-488
[46.]
B.K. Beyer, M.S. Guram, W.F. Geber.
Incidence and potentiation of external and internal fetal anomalies resulting from chlordiazepoxide and amitriptyline alone and in combination.
Teratology, 30 (1984), pp. 39-45
[47.]
G.K. Shopper, M.D. Johnson.
Obstrucción de vías respiratorias e intubación traqueal difícil.
pp. 95-109
[48.]
F.L. Grell, R.A. Koons, J.S. Densons.
Fentanyl in anesthesia: a report of 500 cases.
Anesth Analg, 49 (1970), pp. 523-531
[49.]
A. Hetherington, R.M. Rosenblatt.
Ketamine and paralysis agitant.
Anesthesiology, 52 (1980), pp. 527-531
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
